209 related articles for article (PubMed ID: 38654326)
21. Serum GFAP as a biomarker for disease severity in multiple sclerosis.
Abdelhak A; Huss A; Kassubek J; Tumani H; Otto M
Sci Rep; 2018 Oct; 8(1):14798. PubMed ID: 30287870
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of Plasma Biomarkers for A/T/N Classification of Alzheimer Disease Among Adults of Caribbean Hispanic Ethnicity.
Honig LS; Kang MS; Lee AJ; Reyes-Dumeyer D; Piriz A; Soriano B; Franco Y; Coronado ZD; Recio P; Mejía DR; Medrano M; Lantigua RA; Teich AF; Dage JL; Mayeux R
JAMA Netw Open; 2023 Apr; 6(4):e238214. PubMed ID: 37079306
[TBL] [Abstract][Full Text] [Related]
23. Matching proposed clinical and MRI criteria of aggressive multiple sclerosis to serum and cerebrospinal fluid markers of neuroaxonal and glial injury.
Schaller-Paule MA; Maiworm M; Schäfer JH; Friedauer L; Hattingen E; Wenger KJ; Weber F; Jakob J; Steffen F; Bittner S; Yalachkov Y; Foerch C
J Neurol; 2024 Jun; 271(6):3512-3526. PubMed ID: 38536455
[TBL] [Abstract][Full Text] [Related]
24. Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders.
Olsson B; Portelius E; Cullen NC; Sandelius Å; Zetterberg H; Andreasson U; Höglund K; Irwin DJ; Grossman M; Weintraub D; Chen-Plotkin A; Wolk D; McCluskey L; Elman L; Shaw LM; Toledo JB; McBride J; Hernandez-Con P; Lee VM; Trojanowski JQ; Blennow K
JAMA Neurol; 2019 Mar; 76(3):318-325. PubMed ID: 30508027
[TBL] [Abstract][Full Text] [Related]
25. Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort.
Chatterjee P; Pedrini S; Doecke JD; Thota R; Villemagne VL; Doré V; Singh AK; Wang P; Rainey-Smith S; Fowler C; Taddei K; Sohrabi HR; Molloy MP; Ames D; Maruff P; Rowe CC; Masters CL; Martins RN;
Alzheimers Dement; 2023 Apr; 19(4):1117-1134. PubMed ID: 36574591
[TBL] [Abstract][Full Text] [Related]
26. Alzheimer's and neurodegenerative disease biomarkers in blood predict brain atrophy and cognitive decline.
Dark HE; An Y; Duggan MR; Joynes C; Davatzikos C; Erus G; Lewis A; Moghekar AR; Resnick SM; Walker KA
Alzheimers Res Ther; 2024 Apr; 16(1):94. PubMed ID: 38689358
[TBL] [Abstract][Full Text] [Related]
27. Plasma neurofilament light chain and glial fibrillary acidic protein predict stroke in CADASIL.
Chen CH; Cheng YW; Chen YF; Tang SC; Jeng JS
J Neuroinflammation; 2020 Apr; 17(1):124. PubMed ID: 32321529
[TBL] [Abstract][Full Text] [Related]
28. Core cerebrospinal fluid biomarker profile in cerebral amyloid angiopathy: A meta-analysis.
Charidimou A; Friedrich JO; Greenberg SM; Viswanathan A
Neurology; 2018 Feb; 90(9):e754-e762. PubMed ID: 29386280
[TBL] [Abstract][Full Text] [Related]
29. The relationship between serum neurofilament light chain and glial fibrillary acidic protein with the REM sleep behavior disorder subtype of Parkinson's disease.
Teng X; Mao S; Wu H; Shao Q; Zu J; Zhang W; Zhou S; Zhang T; Zhu J; Cui G; Xu C
J Neurochem; 2023 Apr; 165(2):268-276. PubMed ID: 36776136
[TBL] [Abstract][Full Text] [Related]
30. The relation of a cerebrospinal fluid profile associated with Alzheimer's disease with cognitive function and neuropsychiatric symptoms in sporadic cerebral amyloid angiopathy.
De Kort AM; Kaushik K; Kuiperij HB; Jäkel L; Li H; Tuladhar AM; Terwindt GM; Wermer MJH; Claassen JAHR; Klijn CJM; Verbeek MM; Kessels RPC; Schreuder FHBM
Alzheimers Res Ther; 2024 May; 16(1):99. PubMed ID: 38704569
[TBL] [Abstract][Full Text] [Related]
31. Serum and cerebrospinal fluid brain damage markers neurofilament light and glial fibrillary acidic protein correlate with tick-borne encephalitis disease severity-a multicentre study on Lithuanian and Swedish patients.
Veje M; Griška V; Pakalnienė J; Mickienė A; Bremell D; Zetterberg H; Blennow K; Lindquist L; Studahl M
Eur J Neurol; 2023 Oct; 30(10):3182-3189. PubMed ID: 37431060
[TBL] [Abstract][Full Text] [Related]
32. Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial.
Wagemann O; Liu H; Wang G; Shi X; Bittner T; Scelsi MA; Farlow MR; Clifford DB; Supnet-Bell C; Santacruz AM; Aschenbrenner AJ; Hassenstab JJ; Benzinger TLS; Gordon BA; Coalier KA; Cruchaga C; Ibanez L; Perrin RJ; Xiong C; Li Y; Morris JC; Lah JJ; Berman SB; Roberson ED; van Dyck CH; Galasko D; Gauthier S; Hsiung GR; Brooks WS; Pariente J; Mummery CJ; Day GS; Ringman JM; Mendez PC; St George-Hyslop P; Fox NC; Suzuki K; Okhravi HR; Chhatwal J; Levin J; Jucker M; Sims JR; Holdridge KC; Proctor NK; Yaari R; Andersen SW; Mancini M; Llibre-Guerra J; Bateman RJ; McDade E;
JAMA Neurol; 2024 Jun; 81(6):582-593. PubMed ID: 38683602
[TBL] [Abstract][Full Text] [Related]
33. Plasma GFAP, NfL and pTau 181 detect preclinical stages of dementia.
Ingannato A; Bagnoli S; Mazzeo S; Giacomucci G; Bessi V; Ferrari C; Sorbi S; Nacmias B
Front Endocrinol (Lausanne); 2024; 15():1375302. PubMed ID: 38654932
[TBL] [Abstract][Full Text] [Related]
34. Cerebrospinal Fluid and Plasma Biomarkers do not Differ in the Presenile and Late-Onset Behavioral Variants of Frontotemporal Dementia.
Marelli C; Hourregue C; Gutierrez LA; Paquet C; Menjot de Champfleur N; De Verbizier D; Jacob M; Dubois J; Maleska AM; Hirtz C; Navucet S; Bennys K; Dumurgier J; Cognat E; Berr C; Magnin E; Lehmann S; Gabelle A
J Alzheimers Dis; 2020; 74(3):903-911. PubMed ID: 32083577
[TBL] [Abstract][Full Text] [Related]
35. Serum neurofilament light chain or glial fibrillary acidic protein in the diagnosis and prognosis of brain metastases.
Lin X; Lu T; Deng H; Liu C; Yang Y; Chen T; Qin Y; Xie X; Xie Z; Liu M; Ouyang M; Li S; Song Y; Zhong N; Qiu W; Zhou C
J Neurol; 2022 Feb; 269(2):815-823. PubMed ID: 34283286
[TBL] [Abstract][Full Text] [Related]
36. Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis.
Axelsson M; Malmeström C; Nilsson S; Haghighi S; Rosengren L; Lycke J
J Neurol; 2011 May; 258(5):882-8. PubMed ID: 21197541
[TBL] [Abstract][Full Text] [Related]
37. Plasma NfL and GFAP as biomarkers of spinal cord degeneration in adrenoleukodystrophy.
van Ballegoij WJC; van de Stadt SIW; Huffnagel IC; Kemp S; Willemse EAJ; Teunissen CE; Engelen M
Ann Clin Transl Neurol; 2020 Nov; 7(11):2127-2136. PubMed ID: 33047897
[TBL] [Abstract][Full Text] [Related]
38. Serum GFAP and NfL levels in benign relapsing-remitting multiple sclerosis.
Niiranen M; Kontkanen A; Jääskeläinen O; Tertsunen HM; Selander T; Hartikainen P; Huber N; Solje E; Haapasalo A; Kokkola T; Lohioja T; Herukka SK; Simula S; Remes AM
Mult Scler Relat Disord; 2021 Nov; 56():103280. PubMed ID: 34627002
[TBL] [Abstract][Full Text] [Related]
39. Temporal Ordering of Biomarkers in Dutch-Type Hereditary Cerebral Amyloid Angiopathy.
Koemans EA; Rasing I; Voigt S; van Harten TW; van der Zwet RGJ; Kaushik K; Schipper MR; van der Weerd N; van Zwet EW; van Etten ES; van Osch MJP; Kuiperij B; Verbeek MM; Terwindt GM; Greenberg SM; van Walderveen MAA; Wermer MJH
Stroke; 2024 Apr; 55(4):954-962. PubMed ID: 38445479
[TBL] [Abstract][Full Text] [Related]
40. Is there a CSF biomarker profile related to depression in elderly women?
Gudmundsson P; Skoog I; Waern M; Blennow K; Zetterberg H; Rosengren L; Gustafson D
Psychiatry Res; 2010 Apr; 176(2-3):174-8. PubMed ID: 20132991
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]